Cannabis Bioscience International Holdings, Inc. reported a revenue increase of 21.7% for the fiscal year ending May 31, 2025, generating $303,022 compared to $248,841 in the previous year. The growth was primarily driven by a significant rise in revenues from clinical trial contracts, which rose to $301,731 from $213,865. However, the company faced a decline in revenues from educational classes and seminars, which dropped to $1,291 from $6,335, attributed to fewer classes conducted during the year. The overall operating loss decreased to $421,365 from $486,140, while the net loss improved to $548,820 from $651,345.
In terms of operational changes, the company has made strategic decisions to focus on its clinical trial business and the upcoming launch of its CBD product line, VitaCookies. The company plans to manufacture and market these products in Texas, with a range of cookies aimed at addressing various health conditions. The introduction of VitaCookies is expected to enhance revenue streams and contribute to profitability in the near future. The company has also filed ten utility patent applications related to cannabinoid-based compounds, indicating a commitment to expanding its intellectual property portfolio.
The company’s workforce remains small, with only two full-time employees and approximately 14 independent contractors. This structure reflects a lean operational model as the company navigates its growth phase. Financially, the company reported negative working capital of $916,878 and an accumulated deficit of $5,882,901 as of May 31, 2025. The company has raised capital through private sales of common stock and loans, but it continues to seek additional funding to support its operations and growth initiatives.
Looking ahead, Cannabis Bioscience International Holdings, Inc. aims to leverage its growing portfolio of CBD products and educational services to achieve profitability. The company anticipates that the launch of VitaCookies, along with its educational offerings related to the Texas Compassionate Use Program, will drive substantial revenue growth. However, the company acknowledges the need for significant capital to fund its operations and repay debts, emphasizing the importance of successful execution of its operational plans to ensure its viability as a going concern.
About Cannabis Bioscience International Holdings, Inc.
Cannabis Bioscience International Holdings develops research, education, and clinical trial services focused on medicinal cannabis and CBD products. It offers scientific research, professional training, and digital educational materials to industry professionals, patients, and regulators. The company plans to commercialize CBD edibles under VitaCookies and conducts cannabinoid clinical trials. Its core value lies in advancing biotech and scientific understanding of cannabis for medical applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.